Cite
HARVARD Citation
McKibbin, M. et al. (2012). CFH, VEGF and HTRA1 promoter genotype may influence the response to intravitreal ranibizumab therapy for neovascular age-related macular degeneration. British journal of ophthalmology. 96 (2), pp. 208-212. [Online].